ABL Bio Inc. (298380.KQ)
KRW 64700.0
(-0.31%)
KRW 64700.0
(-0.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.64 Billion KRW | -182.49% |
| 2022 | 3.2 Billion KRW | 107.37% |
| 2021 | -43.55 Billion KRW | 21.67% |
| 2020 | -55.6 Billion KRW | -50.27% |
| 2019 | -37 Billion KRW | 68.44% |
| 2018 | -117.23 Billion KRW | -56.87% |
| 2017 | -74.73 Billion KRW | -446.11% |
| 2016 | -13.68 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.97 Billion KRW | 4.33% |
| 2024 Q2 | -11.4 Billion KRW | 4.7% |
| 2023 FY | -2.64 Billion KRW | -182.49% |
| 2023 Q4 | -12.51 Billion KRW | -204.51% |
| 2023 Q3 | -4.1 Billion KRW | 60.33% |
| 2023 Q2 | -10.35 Billion KRW | -142.57% |
| 2023 Q1 | 24.33 Billion KRW | 236.58% |
| 2022 Q1 | -8.55 Billion KRW | 48.68% |
| 2022 FY | 3.2 Billion KRW | 107.37% |
| 2022 Q4 | -17.81 Billion KRW | -164.91% |
| 2022 Q3 | 27.44 Billion KRW | 1185.96% |
| 2022 Q2 | 2.13 Billion KRW | 124.94% |
| 2021 Q3 | -9.95 Billion KRW | -23.89% |
| 2021 Q2 | -8.03 Billion KRW | 9.55% |
| 2021 Q4 | -16.67 Billion KRW | -67.43% |
| 2021 Q1 | -8.88 Billion KRW | 0.0% |
| 2021 FY | -43.55 Billion KRW | 21.67% |
| 2020 FY | -55.6 Billion KRW | -50.27% |
| 2019 FY | -37 Billion KRW | 68.44% |
| 2018 FY | -117.23 Billion KRW | -56.87% |
| 2017 FY | -74.73 Billion KRW | -446.11% |
| 2016 FY | -13.68 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | -10.38 Billion KRW | 74.509% |
| Hyundai Bioscience Co., Ltd. | -14.49 Billion KRW | 81.746% |
| ST Pharm Co.,Ltd. | 19.58 Billion KRW | 113.516% |
| Cellid, Co., Ltd. | -11.61 Billion KRW | 77.206% |